Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging
- PMID: 19095487
- DOI: 10.1016/j.oraloncology.2008.10.015
Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging
Abstract
After radiotherapy with or without chemotherapy differentiation between residual and recurrent head and neck cancer and (chemo)radiation sequelae is often difficult. Currently, most physicians aggressively pursue potential recurrences, leading to a high rate of futile invasive diagnostic, e.g. examinations under general anaesthesia with taking of biopsies, and surgical procedures, e.g. planned neck dissections, and a waste of health care resources. Therefore, diagnostic techniques which reliably select patients who should undergo these procedures are warranted. Conventional imaging techniques are not reliable enough for this purpose. Potential imaging techniques to detect residual and recurrent locoregional disease after chemoradiation are (serial) CT or MRI and FDG-PET, eventually in combination with specific response criteria or scoring systems. Diffusion MRI and PET/CT may further improve these techniques. FDG-PET may help to select patients clinically suspected of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy under general anaesthesia. It is not yet clear whether FDG-PET can reliable avoid futile routine evaluation by examination under general anaesthesia in oral and oropharyngeal cancer and planned neck dissection when a residual mass persists in the neck after (chemo)radiation. The most reliable scoring criteria and the optimal time interval between completion of radiation and FDG-PET still has to be assessed.
Similar articles
-
Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting.Radiographics. 2011 Mar-Apr;31(2):355-73. doi: 10.1148/rg.312095765. Radiographics. 2011. PMID: 21415184 Review.
-
Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4-6 months after radiotherapy to assess residual head-and-neck cancer.Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e825-32. doi: 10.1016/j.ijrobp.2010.11.072. Epub 2011 Feb 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 21300450
-
PET monitoring of therapy response in head and neck squamous cell carcinoma.J Nucl Med. 2009 May;50 Suppl 1:74S-88S. doi: 10.2967/jnumed.108.057208. Epub 2009 Apr 20. J Nucl Med. 2009. PMID: 19380408 Review.
-
Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.Ann Surg Oncol. 2011 Sep;18(9):2579-84. doi: 10.1245/s10434-011-1655-x. Epub 2011 Mar 16. Ann Surg Oncol. 2011. PMID: 21409485
-
Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.Oral Oncol. 2013 May;49(5):449-53. doi: 10.1016/j.oraloncology.2012.12.007. Epub 2013 Jan 12. Oral Oncol. 2013. PMID: 23321549
Cited by
-
Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma.Eur Arch Otorhinolaryngol. 2013 May;270(5):1569-80. doi: 10.1007/s00405-012-2172-7. Epub 2012 Sep 13. Eur Arch Otorhinolaryngol. 2013. PMID: 22972497 Review.
-
Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers.Eur Radiol. 2013 Feb;23(2):562-9. doi: 10.1007/s00330-012-2596-x. Epub 2012 Aug 4. Eur Radiol. 2013. PMID: 22865270
-
MRI in head and neck cancer following chemoradiotherapy: what is the optimal delay to demonstrate maximal response?Eur Radiol. 2021 Dec;31(12):9273-9286. doi: 10.1007/s00330-021-07913-x. Epub 2021 May 19. Eur Radiol. 2021. PMID: 34009413 Free PMC article.
-
Diagnostic performance of core needle biopsy for nodal recurrences in patients with head and neck squamous cell carcinoma.Sci Rep. 2022 Feb 7;12(1):2048. doi: 10.1038/s41598-022-06102-0. Sci Rep. 2022. PMID: 35132145 Free PMC article.
-
Expression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohistochemical Study.J Clin Diagn Res. 2015 Nov;9(11):ZC66-9. doi: 10.7860/JCDR/2015/12777.6836. Epub 2015 Nov 1. J Clin Diagn Res. 2015. PMID: 26675878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical